
Oncology NEWS International
- Oncology NEWS International Vol 7 No 12
- Volume 7
- Issue 12
Full FDA Approval for Camptosar
ROCKVILLE, Md-The FDA has granted full approval to Pharmacia & Upjohn’s Camptosar (irinotecan), based on survival data. Camptosar is indicated for use in patients with metastatic colorectal cancer whose disease has recurred or spread after treatment with the current standard chemotherapy. The agent received accelerated FDA approval in June 1996.
ROCKVILLE, MdThe FDA has granted full approval to Pharmacia & Upjohns Camptosar (irinotecan), based on survival data. Camptosar is indicated for use in patients with metastatic colorectal cancer whose disease has recurred or spread after treatment with the current standard chemotherapy. The agent received accelerated FDA approval in June 1996.
Articles in this issue
over 27 years ago
Long-Term Adjuvant Tamoxifen Urged for Low-Risk Breast Cancerover 27 years ago
EORTC DCIS Study Confirms Recurrence Reduction With RTover 27 years ago
James Cancer Center Joins NCCN Outcomes Databaseover 27 years ago
Managed Care Sees Need for National Guidelines, Accreditationover 27 years ago
Advisory Panel Recommends Approval of Vysis HER2 Testover 27 years ago
Drinking Tea After Smoking May Reduce Oxidative Stressover 27 years ago
Use Special Skills, Tools to Assess Pain in Children, Elderlyover 27 years ago
Good Response Rates With Radiolabeled Anti-CD20 MoAB in NHLover 27 years ago
Tobacco Industry Settles With StatesNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.























































